There are currently 1093 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
Recruiting
The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.(e.g. Velora Pioneer)
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/11/2025
Locations: Mayo Clinic - Rochester, Rochester, Minnesota
Conditions: Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3, Von Willebrand Disease, Type 2A, Von Willebrand Disease, Type 2M, Von Willebrand Disease, Type 2N
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Recruiting
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/11/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cutaneous Venous Malformations
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
Recruiting
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
08/11/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes
Post COVID-19 Syndrome Treatment With Variable Pulse Transcranial Magnetic Stimulation
Recruiting
The purpose of this study is to test if Variable Pulse TMS (Transcranial Magnetic Stimulation) can result in objective improvements in patients with Post COVID Syndrome (PCS).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/11/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Post COVID-19 Condition
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
Recruiting
The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Mayo Clinic - Rochester, Rochester, Minnesota
Conditions: Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
Contrast Echocardiography During Exercise to Assess Pulmonary Blood Volume
Recruiting
The purpose of this study is to evaluate whether pulmonary blood volume (PBV) derived from contrast echocardiography can serve as a non-invasive surrogate for invasive pulmonary artery wedge pressure (PAWP) during exercise. Also, to compare changes in PBV with exercise in patients with and without heart failure and pulmonary vascular disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Heart Failure, Pulmonary Vascular Disease
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
Recruiting
This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the body (advanced). PSMA is a protein that appears in large amounts on the surface of liver cancer cells. The radioactive chemical compound (68Ga-PSMA) has been designed to circulate through the body and attach itself to the PSMA protein on liver cancer cells. A PET scan i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
Recruiting
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
08/11/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Peanut Allergy
Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients
Recruiting
This study evaluates endocrine therapy-induced alopecia among postmenopausal and premenopausal female patients with breast cancer. Alopecia is one of the most feared side effects of cancer-directed therapy, causing distress in women starting treatment for breast cancer. While alopecia is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing endocrine therapy. Despite the frequent reports of alopecia related to endocrine therapy, hair loss is rarely re... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Breast Carcinoma
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Recruiting
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies ha... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
08/11/2025
Locations: Mayo Clinic - Rochester /ID# 258295, Rochester, Minnesota
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Recruiting
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/11/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy